PR 2100
Alternative Names: PR-2100Latest Information Update: 20 Jun 2023
At a glance
- Originator Prometheus Biosciences
- Developer Cellaion
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 16 Jun 2023 Prometheus Biosciences has been acquired and merged into Merck & Co
- 05 May 2023 Prometheus Biosciences plans to file an IND application for Inflammatory bowel disease by the end of 2024
- 11 Apr 2023 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral) (Prometheus Biosciences pipeline, April 2023)